Patient characteristics at baseline
| Characteristics | BUD 100 μg twice daily |
BUD 200 μg once daily | BUD 100 μg once daily | Placebo |
| Number of patients | 28 | 32 | 28 | 34 |
| Boys/girls | 18/10 | 17/15 | 23/5 | 22/12 |
| Age (y) | 10.2 | 10.0 | 9.5 | 9.4 |
| Height (cm) | 145.6 | 145.6 | 139.3 | 138.7 |
| Number of atopics | 20 | 21 | 20 | 26 |
| FEV1 (l) | 2.27 (0.57) | 2.23 (0.66) | 2.30 (0.85) | 2.04 (0.67) |
| FEV1 % of pred | 106.0 (14.1) | 102.1 (11.4) | 102.2 (12.8) | 104.6 (12.9) |
| Reversibility in FEV1 (%) | 4.3 (3.8) | 3.6 (3.4) | 2.4 (2.8) | 3.8 (3.1) |
| PEF morning (l/min) | 263.8 (62.2) | 260.4 (84.2) | 259.9 (85.4) | 229.5 (75.9) |
| Methacholine PD20(μmol) | 3.75 | 4.33 | 5.83 | 4.04 |
| Maximum fall in FEV1 (%) after exercise test | 10.6 (8.1) | 13.7 (12.4) | 14.7 (17.5) | 10.1 (9.6) |
Results are given as mean (SD).
BUD, budesonide; FEV1, forced expiratory volume in 1 second; PEF, peak expiratory flow; PD20 provocative dose causing a 20% fall in FEV1.